IP Library Granted Patent US 9,694,057
Granted Patent B2
US 9,694,057 · App. 14/743,427 · Granted Jul 4, 2017

Stabilized compositions of proteins having a free thiol moiety

Inventors: Gaozhong Zhu (Weston, MA); Vinh Nguyen (Chelsea, MA); Kris Lowe (Boston, MA); Zahra Shahrokh (Weston, MA)
Assignee: SHIRE HUMA GENETIC THERAPIES, INC.
A61K38/47A61K9/0019A61K9/19A61K31/7012A61K38/1825A61K47/20A61K47/26A61K47/34B65B3/003B65B31/04C12Y302/01045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,694,057
App. No.
14/743,427
Granted
Jul 4, 2017
Kind
B2
Abstract

Compositions of proteins having free thiols, and methods of making and using such compositions, are described.

Claims (29)

1. A method of producing a composition comprising glucocerebrosidase (GCB), the method comprising providing a GCB preparation and formulating the GCB with a carbohydrate, wherein the carbohydrate is present in an amount sufficient to maintain the stability of the GCB, wherein the carbohydrate is sucrose or trehalose, and wherein the pH of the composition is less than 7.0.

2. The method of claim 1 , wherein the stability is at least 5-80% greater, under pre-selected conditions, than the stability of a composition which differs by lacking the carbohydrate.

3. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to increase the stability of the GCB.

4. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to inhibit the reaction of a free thiol on a first molecule of the GCB with a free thiol on a second molecule of the GCB to form an aggregate.

5. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to inhibit the formation of an aggregate formed by the reaction of a free thiol on a first molecule of the GCB with a free thiol on a second molecule of the GCB by at least 5-80%, under pre-selected conditions, as compared to the same composition lacking the carbohydrate.

6. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient that upon storage, in a gas tight container, at a temperature of 2-8° C., for a period of months, the composition will retain at least 85% of the stability the composition had prior to storage.

7. The method of claim 6 , wherein the storage occurs in darkness.

8. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising sucrose, 0.01% polysorbate-20, pH 6.0, 50 mM Citrate.

9. The method of claim 1 , wherein the carbohydrate is present in an amount sufficient to maintain biochemical integrity and bioactivity characteristics of the GCB.

10. The method of claim 1 , wherein the pH of the composition is between about 4.5 and about 6.5.

11. The method of claim 1 , wherein the composition further comprises an antioxidant, wherein the antioxidant and the carbohydrate are present in amounts sufficient to maintain the stability of the GCB.

12. The composition of claim 11 , wherein the antioxidant is cysteine, cysteine-HCl, or methionine.

13. The method of claim 1 , wherein the composition further comprises a surfactant.

14. The method of claim 13 , wherein the surfactant is poloxamer 188.

15. The method of claim 1 , wherein the composition contains less than about 10% of O 2 .

16. The method of claim 1 , further comprising physical removal of O 2 from the composition.

17. The method of claim 1 , wherein the GCB has two, three, or more free thiol groups and has zero, two, four, or more thiol groups which form sulfhydryl bridges, per active unit of GCB.

18. The method of claim 1 , further comprising exposing the composition to an inert gas, wherein the inert gas is present in a concentration higher than in the ambient atmosphere.

19. The method of claim 1 , further comprising packaging the composition.

20. The method of claim 19 , wherein the packaging comprises contacting the GCB with an inert gas to reduce the amount of a reactive species, and introducing the GCB, the inert gas, and the carbohydrate into a gas tight container.

21. The method of claim 20 , wherein the container comprises a headspace comprising at least 90% (vol/vol) an inert gas.

22. The method of claim 21 , wherein the container is a prefilled syringe, a vial, or ampoule.

23. The method of claim 22 , wherein the prefilled syringe is a needleless syringe.

24. The method of claim 20 , wherein the inert gas is N 2 or Ar and the reactive species is O 2 .

25. The method of claim 1 , wherein the composition is a liquid.

26. The method of claim 22 , wherein carbohydrate is present at between about 1 and about 40% (wt/vol).

27. The method of claim 22 , wherein the antioxidant is present at between about 0.001 and about 10% (wt/vol).

28. The method of claim 22 , wherein the composition comprises about 0.1-40 mg/ml GCB, about 0.001-10% cysteine, about 1-40% sucrose, at a pH of about 5.5-6.0, and wherein the level of dissolved O 2 is less than about 10%.

29. The method of claim 1 , wherein the composition does not comprise polysorbate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 061255/0278 →
CHANGE OF ADDRESS Recorded May 25, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 042582/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2016
From: ZHU, GAOZHONG; NGUYEN, VINH T.; LOWE, KRIS; SHAHROKH, ZAHRA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 038583/0256 →
Continuity (5)
Division 14019850 · Sep 6, 2013
Continuation 12902680 · Oct 12, 2010
Continuation 11671588 · Feb 6, 2007
Provisional Application 60771555 · Feb 7, 2006
Related Publication 20150283216A1 · Oct 8, 2015